ASH 2014: Expert discussion on the latest in AML
ASH 2014: Expert discussion on the latest in AML
Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma
ASH 2014: Expert discussion on the latest in CLL
Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma
Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study
Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study
Stem cell transplantation safe for patients with HIV-associated lymphoma
Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study
Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study
Children with aggressive leukaemia experiencing remission with T cell therapy
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy
Overall survival update from the BREAK-3 study